Mycobacterium vaccae for Injection 22.5?µg Vial – For Research Use Only

Description

Mycobacterium vaccae (trade name Vaccae™) is a heat?killed preparation of a non?tuberculosis mycobacterium, first approved in China in 2001 as an adjunctive immunotherapeutic agent for pulmonary tuberculosis. It enhances both innate and adaptive immunity via Th1 activation, macrophage stimulation, and cytokine modulation. Multiple meta-analyses and phase III clinical trials demonstrate improved sputum conversion, lesion resolution, and safety in TB patients. In preclinical research, Vaccae™ is used to model tuberculosis immunotherapy, trained innate immune response, vaccine adjuvant effects, and host resistance. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Vaccae™ stimulates immune training via macrophage and dendritic cell activation, increasing Th1 cytokines such as IFN?, IL?2, and TNF?, enhancing T?cell and NK cell activity, and promoting antigen-specific immune memory. In research settings, it is used for tuberculosis immunotherapy modeling, vaccine enhancer studies, trained immunity investigations, and adjunctive treatment protocols in chronic infection models.

Side Effects (For Reference Only in Research Models)

Mild local reactions such as injection-site redness, induration, or transient fever are observed in clinical use. Rare systemic side effects include lymphadenopathy or localized inflammatory responses. These data inform biosafety precautions in experimental models.

Disclaimer

Mycobacterium vaccae Injection is strictly intended for laboratory research use only. Not for human or veterinary therapeutic, diagnostic, or prophylactic use.